PacBio Earnings Call: Consumables Strength Amid Headwinds

Pacific Biosciences ((PACB)) has held its Q4 earnings call. Read on for the main highlights of the call.

Pacific Biosciences’ latest earnings call struck a cautiously optimistic tone as management balanced solid operational progress with ongoing financial and market pressures. Executives highlighted record consumable sales, expanding margins and sharply lower cash burn, even as net losses remained sizable and instrument demand felt the pinch from weak academic funding, especially in the Americas.

Revenue Rebound in Q4 Caps a Mixed Year

PacBio reported Q4 2025 revenue of $44.6 million, up 14% year over year and 16% sequentially, fueled by stronger Revio and Vega system sales and surging consumables demand. For the full year, however, revenue reached $160 million, just 4% higher than 2024, underscoring how softness in capital budgets restrained overall growth.

Consumables Hit Records and Lead the Growth Story

Consumables remained the standout growth engine, with Q4 revenue hitting a record $21.6 million, up 15% from the prior year. For 2025, consumables climbed to $82 million, a 16% annual increase, with shipments up 19% and clinical and hospital customers delivering an impressive 55% growth in consumables usage.

Gross Margins Strengthen on Scale and Mix

Non‑GAAP gross margin improved to 40% in Q4 and for full‑year 2025, up from 31% and 33% in the prior-year periods, respectively. Management pointed to a 1,300 basis point expansion since 2023 and a 700 basis point gain in 2025 alone, driven by scale, higher consumables mix and cost efficiencies, although component cost volatility remains a risk.

Platform Shipments Show Momentum, Especially Vega

In Q4, PacBio shipped 21 Revio and 42 Vega instruments, bringing totals to 331 Revio and 147 Vega systems in the field. Vega showed particularly strong traction, with about 65% of 2025 placements going to customers new to PacBio, broadening adoption of its HiFi long-read technology across fresh accounts.

SparkNex Promises Cheaper, Higher-Throughput Genomes

SparkNex, the company’s next‑generation chemistry and multi‑use SMRT Cell, showed beta results with 25% higher output per SMRT Cell alongside better yields and read quality. Management reiterated its target of delivering whole‑genome HiFi sequencing at scale for under $300 per genome, with a broader commercial launch aimed for 2026.

Clinical and Population Programs Deepen Demand Pipeline

The call highlighted growing traction in clinical and population sequencing, citing programs at the University of Washington, the Ambry ONCE study, and inclusion in broader initiatives such as IHOPE and Babies in Focus. Large-scale population projects like All of Us, the Long Life Family Study and the Asian Pan‑Genome are reinforcing PacBio’s role in complex genomics research.

Operating Discipline Reduces Expenses and Cash Burn

Non‑GAAP operating expenses fell to $229.9 million in 2025 from $289.2 million in 2024, a 20% year‑on‑year reduction that reflects restructuring and tighter cost control. Cash burn excluding financings and acquisitions improved to $105 million from $214 million in 2023, a 51% improvement over two years and 44% better than last year.

Balance Sheet Bolstered but Cash Still Trending Lower

PacBio strengthened its balance sheet by selling short‑read sequencing assets, generating about $48 million in net proceeds and sharpening focus on its long‑read strategy. Even so, unrestricted cash, cash equivalents and investments declined to roughly $279.5 million at the end of 2025, down from $389.9 million a year earlier as the business continues to fund its operations.

Instrument Revenue Slides Amid Academic Spending Slump

Despite strong Q4 activity, full‑year 2025 instrument revenue dropped 18% to $53.8 million as academic capital budgets tightened, particularly for Revio systems. Management said it does not expect a meaningful near‑term recovery in academic funding, which has weighed on system placements and leaves consumables to shoulder more of the growth load.

Losses Narrow but Profitability Still a Distant Goal

PacBio’s non‑GAAP net loss narrowed to $158.8 million in 2025 from $228 million in 2024, showing meaningful progress but still reflecting substantial red ink. In Q4, the company posted a non‑GAAP net loss of $37.6 million, or $0.12 per share, underscoring that margin gains and cost cuts have not yet brought the business close to break-even.

Pricing Pressure and Component Costs Pose Margin Risks

Some Revio units were placed at lower prices in Q4 with strategic and multi-system discounts, keeping Q4 Revio ASP at about $482,000 and raising the prospect of future pricing pressure. Management also warned about volatility in compute and memory component costs for Revio and Vega, which could partially offset expected margin improvements if input prices spike.

Restructuring Lowers Headcount but Adds Execution Risk

Headcount fell to 485 employees at year‑end 2025 from 575 a year earlier, a 16% reduction that supports lower operating expenses. While management framed this as necessary streamlining, they acknowledged that ongoing restructuring and leaner staffing raise execution risks as the company pushes new products like SparkNex and scales clinical initiatives.

Conservative Outlook Anchored by Consumables and SparkNex

For 2026, PacBio guided revenue to $165 million to $180 million, implying about 8% growth at the midpoint, driven mainly by consumables and early contributions from SparkNex in the second half. The company expects non‑GAAP gross margin to improve by 100 to 400 basis points and operating expenses to tick down slightly from 2025 levels, with guidance reflecting continued weak academic spending, potential component cost volatility and a gradual march toward cash‑flow breakeven.

PacBio’s earnings call depicted a company leaning into its strengths—rising consumables usage, expanding gross margins and improving cash discipline—while still wrestling with structural headwinds in instrument demand and persistent losses. For investors, the story hinges on whether clinical and population genomics, combined with SparkNex’s promise of cheaper, higher‑throughput sequencing, can convert today’s operational gains into durable, profitable growth over the next few years.